Editors: Thomas C. Chen, Marc Chamberlain

Series Title: Controversies in Neuro-Oncology

Avastin and Malignant Gliomas

Volume 1

eBook: US $79 Special Offer (PDF + Printed Copy): US $158
Printed Copy: US $119
Library License: US $316
ISSN: 2210-5565 (Print)
ISBN: 978-1-60805-519-7 (Print)
ISBN: 978-1-60805-132-8 (Online)
Year of Publication: 2010
DOI: 10.2174/97816080513281100101


Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small scale phase I/II trials performed have proved to be inconclusive because of the limited number of patients involved. As a result, many controversies exist in neuro-oncology drug development for which a forum does not exist. This ebook presents a detailed account on the use of avastin in treating cancer patients. A discussion on clinical experiences and the controversial debate among researchers of avastin's role in restricting malignant gliomas is also included giving readers a diverse perspective on the rationale of treating CNS tumors.

Indexed in: Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.


- Pp. i
Victor A. Levin
Download Free


- Pp. ii-iiii (2)
Thomas Chen
Download Free


- Pp. iv-vii (4)
Thomas C. Chen, Marc Chamberlain
Download Free

The Basic Science of Avastin (Bevacizumab) Therapy

- Pp. 1-6 (6)
Florence M. Hofman, Thomas C. Chen
View Abstract

Avastin for Recurrent Malignant Gliomas

- Pp. 7-11 (5)
Annick Desjardins, James J. Vredenburgh
View Abstract

Avastin and Malignant Gliomas: Is there a Role?

- Pp. 12-18 (7)
Teri N. Kreisl
View Abstract

Bevacizumab with Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

- Pp. 19-23 (5)
Fabio M. Iwamoto, Philip H. Gutin
View Abstract

Bevacizumab Failure in Patients with Recurrent Malignant Glioma

- Pp. 24-27 (4)
Andrew D. Norden
View Abstract

An Update on the Role of Anti-Angiogenic Therapy for Newly Diagnosed Glioblastoma

- Pp. 28-32 (5)
David A. Reardon, Sith Sathornsumetee, James V. Vredenburgh
View Abstract

Bevacizumab Plus Radiotherapy in Malignant Gliomas: Is there a Role?

- Pp. 33-39 (7)
Minesh Mehta, Disha Patel, Arnab Chakravarti
View Abstract

Bevacizumab and Malignant Glioma: Is there a Role for Upfront Therapy?

- Pp. 40-45 (6)
Jing Wu, Mark R. Gilbert
View Abstract

Bevacizumab Toxicity in Glioblastoma

- Pp. 46-50 (5)
Dawit Aregawi, David Schiff
View Abstract

Is Bevacizumab Administration Safe When Combined with Therapeutic Anticoagulation in Patients with High-grade Glioma?

- Pp. 51-53 (3)
Lisa R. Rogers
View Abstract

Bevacizumab in the Treatment of Glioblastoma: Is there an Optimal Dose or Schedule?

- Pp. 54-58 (5)
L. Kamsheh, P. Kumthekar, J. J. Raizer
View Abstract

Assessing Radiographic Response in Glioblastoma Following Avastin Treatment

- Pp. 59-73 (15)
Whitney B. Pope
View Abstract

The Radiographic Interpretation of Response to Avastin in Glioblastoma Multiforme

- Pp. 74-80 (7)
Nicholas Butowski, Susan Chang
View Abstract

Imaging Responses of Bevacizumab

- Pp. 81-93 (13)
R. Thind, Y. S. Mohan, T. Mikkelsen
View Abstract

Assessing Radiographic Response to Bevacizumab in Patients with GBM

- Pp. 94-99 (6)
John W. Henson, Bart Keogh
View Abstract

Neurosurgical Implications of Bevacizumab Therapy of Malignant Gliomas

- Pp. 100-106 (7)
Manish K. Aghi, Mitchel S. Berger
View Abstract

Neurosurgical Implications of Avastin

- Pp. 107-110 (4)
Gazanfar Rahmathulla, Michael A. Vogelbaum
View Abstract

Novel Applications for Bevacizumab and other Angiogenic Inhibitors

- Pp. 111-116 (6)
Marc C. Chamberlain
View Abstract

Role of Avastin for Treatment of Central Nervous System Radiation Necrosis

- Pp. 117-126 (10)
Jing Wu, Victor A. Levin
View Abstract

Salvage Chemotherapy with Bevacizumab for Recurrent Anaplastic Glioma

- Pp. 127-132 (6)
Marc C. Chamberlain
View Abstract

Bevacizumab for Recurrent Glioma - A Personal View

- Pp. 133-139 (7)
Roger Stupp
View Abstract

Inhibitors of VEGF Signaling Pathways in Glioblastoma: Is the Evidence Sufficient for Widespread Use? A European Perspective

- Pp. 140-143 (4)
M. J. van den Bent
View Abstract

Bevacizumab (AvastinĀ®) and Malignant Glioma: Is there a Role? A European Perspective

- Pp. 144-146 (3)
Michael Weller
View Abstract

The European Perspective Regarding Avastin and Malignant Gliomas

- Pp. 147-151 (5)
Wolfgang Wick, Michael Platten, Antje Wick
View Abstract

Sunitinib for the Treatment of Central Nervous System Glioma

- Pp. 152-157 (6)
Neyns Bart
View Abstract

Cilengitide: A Novel Integrin Antagonist, in Malignant Glioma

- Pp. 158-161 (4)
L. Burt Nabors
View Abstract

Development of Sorafenib in Malignant Gliomas: Rationale and Early Clinical Experience

- Pp. 162-170 (9)
Rachel Grossman, Jaishri Blakeley
View Abstract

Aflibercept (VEGF-Trap) in High-Grade Gliomas

- Pp. 171-175 (5)
Jan Drappatz, Andrew D. Norden, Patrick Y. Wen
View Abstract

Cediranib in Glioblastoma

- Pp. 176-183 (8)
Elizabeth R. Gerstner, Jorg H. Dietrich, Daphne Wang, Tracy T. Batchelor
View Abstract

Bevacizumab for Malignant Gliomas: Comparative Study with Other Malignancies

- Pp. 184-189 (6)
Helen Gu, Thomas C. Chen
View Abstract

Author Index

- Pp. 190-191 (2)
Thomas C. Chen, Marc Chamberlain
Download Free


- Pp. 192-195 (4)
Bentham Science Publishers
Download Free


.Colorectal Cancer Diagnosis and Therapeutic Updates.
.Nanotherapeutics for the Treatment of Hepatocellular Carcinoma.
.Topics in Anti-Cancer Research.
.Frontiers in Clinical Drug Research - Anti-Cancer Agents.